<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336539">
  <stage>Registered</stage>
  <submitdate>15/02/2011</submitdate>
  <approvaldate>16/02/2011</approvaldate>
  <actrnumber>ACTRN12611000183987</actrnumber>
  <trial_identification>
    <studytitle>Efficacy of continuous preperitoneal infusion of ropivacaine in laparoscopic colorectal surgery</studytitle>
    <scientifictitle>Efficacy of postoperative continuous preperitoneal infusion of 0.5% ropivacaine at 4ml/hr after laparoscopic colorectal surgery compared to intravenous patient controlled  postoperative analgesia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>This study investigates postoperative analgesic efficacy and recovery in patients receiving continuous preperitoneal ropivacaine infusion vs. intravenous patient controlled analgesia after laparoscopic colorectal surgery.</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intervention consists preperitoneal placement of catheter with multiple side-holes to continuously release 0.5%ropivacaine at 4ml/hr for postoperative 72hours. This placement will be conducted by an experienced attending surgeon. 

Intervention with 0.5% ropivacaine (local anesthetics) continuous infusion at 4ml/hr 
</interventions>
    <comparator>Control : IV PCA regimen includes fentanyl 16 mcg/ml in 100ml saline bag with basal infusion rate of 0.5 ml/hr, bolus of 1ml at 15min lockout interval. Thus maximum dose allowed per hour is 80mcg and basal infusion is continued with bolus injection when patient presses a button. Overall duration of this method is 72 hours postoperatively. </comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Decrease in Visual analogue scale (VAS)</outcome>
      <timepoint>postoperative 2hr, 6hr, 24hr, 48hr, 72hr</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>return of bowel movement (flatus)</outcome>
      <timepoint>exact time checking during postoeprative period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>reduced consumption of rescue analgesics</outcome>
      <timepoint>postoeprative 2hr, 6hr, 24hr, 48hr, 72hr</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>ASA PS 2-3 patients undertaking laparoscopic colorectal surgery</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>patients with previous opioid analgesic medication
allergic to local anesthetics or opioid
coagulopathy or hemostatic abnormalities
neurologic disorder / mental disorder
obesity BMI &gt; 30</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients are randomly allocated to one of two groups by using computer based randomized number concealed in an envelop before intervention. All patients receive preperitoneal wound catheterization and IV PCA (intravenous patient controlled analgesia ) device, but one group with study drug only in preperitoneal catheter and the other group with study drug only in IV PCA. Allocation  is blinded both to patients and investigators.</concealment>
    <sequence>Consecutive patients receiving laparoscopic colorectal surgery will be enrolled with randomization sequence generation using computerized randomizer.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/04/2011</anticipatedstartdate>
    <actualstartdate>8/06/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>9/04/2013</actualenddate>
    <samplesize>46</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Korea, Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Samsung Medical Center</primarysponsorname>
    <primarysponsoraddress>50 Ilwon dong, Gangnam gu, 135-710 
Samsung Seoul Hospital</primarysponsoraddress>
    <primarysponsorcountry>Korea, Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Samsung Medical Center</fundingname>
      <fundingaddress>50 Ilwon dong, Gangnam gu, 135-710 
Samsung Seoul Hospital</fundingaddress>
      <fundingcountry>Korea, Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>B. Braun Korea Co., Ltd.</sponsorname>
      <sponsoraddress>13th Fl., West Wing, POSCO Center Bldg. 892, Daechi4-Dong, Kangnam-Ku, Seoul 135-777</sponsoraddress>
      <sponsorcountry>Korea, Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This controlled double blinded randomized clinical study intend to investigate postoperative analgesia and bowel recovery thus overall recovery efficacy of continuous preperitoenal infusion of 0.5% ropivacaine compared to intravenous opioid based patient controlled postoeprative analgesia.  The main hypothesis of this study is that analgesic method using local anesthetic will provide equivalent or better analgesia with prompt bowel recovery.</summary>
    <trialwebsite />
    <publication>under manuscript preparation</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Samsung Medical Center IRB</ethicname>
      <ethicaddress>50 Ilwon dong, Gangnam gu, 135-710 
Samsung Seoul Hospital</ethicaddress>
      <ethicapprovaldate>13/12/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>25/10/2010</ethicsubmitdate>
      <ethiccountry>Korea, Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Woo Seog Sim</name>
      <address>50 Ilwon dong, Gangnam gu, 135-710 
Samsung Seoul Hospital</address>
      <phone>+82-2-3410-1935</phone>
      <fax />
      <email>anesthe@skku.edu</email>
      <country>Korea, Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Sang Hyun Lee</name>
      <address>50 Ilwon dong, Gangnam gu, 135-710 
Samsung Seoul Hospital</address>
      <phone>+82-2-3410-2470</phone>
      <fax />
      <email>shsara.lee@gmail.com</email>
      <country>Korea, Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Sang Hyun Lee</name>
      <address>50 Ilwon dong, Gangnam gu, 135-710 
Samsung Seoul Hospital</address>
      <phone>+82-2-3410-2470</phone>
      <fax />
      <email>withj95@naver.com</email>
      <country>Korea, Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Woo Seog Sim</name>
      <address>50 Ilwon dong, Gangnam gu, 135-710 Samsung Seoul Hospital </address>
      <phone>+82-3410-2470</phone>
      <fax />
      <email>anesthe@skku.edu</email>
      <country>Korea, Republic Of</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>